| Literature DB >> 28396279 |
Gregor Fuhrmann1, Anna Lena Neuer2, Inge K Herrmann2.
Abstract
Extracellular vesicles (EVs) have gained increasing attention as novel disease biomarkers and as promising therapeutic agents. These cell-derived, phospholipid-based particles are present in many - if not all - physiological fluids. They have been shown to govern several physiological processes, such as cell-cell communication, but also to be involved in pathological conditions, for example tumour progression. In infectious diseases, EVs have been shown to induce host immune responses and to mediate transfer of virulence or resistance factors. Here, we discuss recent developments in using EVs as diagnostic tools for infectious diseases, the development of EV-based vaccines and the use of EVs as potential anti-infective entity. We illustrate how EV-based strategies could open a viable new avenue to tackle current challenges in the field of infections, including barrier penetration and growing resistance to antimicrobials.Entities:
Keywords: Antibiotic resistance; Biosensing; Drug therapy; Exosomes; Immune response
Mesh:
Substances:
Year: 2017 PMID: 28396279 DOI: 10.1016/j.ejpb.2017.04.005
Source DB: PubMed Journal: Eur J Pharm Biopharm ISSN: 0939-6411 Impact factor: 5.571